MicroRNA Modulation in Pancreatic Cancer

Pancreatic cancer, including pancreatic ductal adenocarcinoma, remains one of the most lethal malignancies due to late-stage diagnosis, aggressive metastasis and pronounced resistance to conventional treatments. MicroRNAs (miRNAs) are small non-coding RNAs that fine-tune gene expression post-transcriptionally and have been implicated in virtually all hallmarks of cancer. Dysregulation of specific miRNAs can either promote oncogenesis (oncomiRs) or enforce tumour suppression (TsmiRs), influencing cell proliferation, apoptosis, invasiveness, and the tumour microenvironment. In pancreatic cancer, aberrant miRNA expression profiles are observed in both tumour epithelial cells and the stromal compartment, where they contribute to epithelial–mesenchymal transition, immune evasion, and altered extracellular matrix remodelling. Moreover, miRNAs are detectable in biofluids, rendering them attractive as minimally invasive biomarkers for early detection, prognostic stratification and treatment monitoring. In parallel, therapeutic strategies are being developed to restore TsmiR function using synthetic mimics or to inhibit oncomiRs via antagomirs, often in combination with standard chemotherapeutic regimes such as gemcitabine or FOLFIRINOX. Delivery platforms, including lipid nanoparticles, viral vectors and exosomes, are under investigation to overcome cellular uptake barriers and off-target effects. Collectively, microRNA modulation offers a multifaceted approach to disrupt key resistance mechanisms and metastatic pathways, heralding a new horizon in personalised management of pancreatic cancer.

Research from Nature Portfolio

Recent studies have delineated the tumour-suppressive role of miR-34a in pancreatic cancer by demonstrating its capacity to inhibit epithelial–mesenchymal transition and Notch signalling. Restoring miR-34a in pancreatic cancer cell lines reduced Snail1 and Notch1 expression, leading to diminished cell migration, invasion and enhanced apoptosis in vitro, as well as delayed tumour growth in vivo. These findings underscore the potential of targeted re-activation of endogenous tumour suppressor miRNAs to counteract aggressive phenotypes and chemoresistance.

MicroRNA Modulation in Pancreatic Cancer publication trend

The graph below shows the total number of articles in microrna modulation in pancreatic cancer across all publications each year (not limited to Nature Index journals).

Technical terms

microRNA (miRNA): A short non-coding RNA molecule that regulates gene expression by binding to messenger RNA, leading to degradation or translational repression.

oncomiR: A microRNA whose overexpression promotes oncogenic pathways, such as cell survival, proliferation or metastasis.

tumour suppressor microRNA (TsmiR): A microRNA that inhibits cancer development by targeting oncogenes or factors essential for tumour growth.

Epithelial–mesenchymal transition (EMT): A cellular programme in which epithelial cells acquire mesenchymal traits, enhancing motility and invasiveness.

Tumour microenvironment (TME): The complex milieu surrounding tumour cells, including stromal cells, immune cells, extracellular matrix and signalling molecules.

Chemoresistance: The ability of cancer cells to withstand the effects of chemotherapeutic agents, often leading to treatment failure.

References

1. Targeting miRNA and using miRNA as potential therapeutic options to bypass resistance in pancreatic ductal adenocarcinoma. Cancer and Metastasis Reviews (2023).
2. Functional and Potential Therapeutic Implication of MicroRNAs in Pancreatic Cancer. International Journal of Molecular Sciences (2023).
3. microRNAs Associated with Gemcitabine Resistance via EMT, TME, and Drug Metabolism in Pancreatic Cancer. Cancers (2023).
4. Noncoding RNAs: an emerging modulator of drug resistance in pancreatic cancer. Frontiers in Cell and Developmental Biology (2023).
5. MicroRNA in Pancreatic Cancer: From Biology to Therapeutic Potential. Genes (2019).
6. miR-34a inhibits pancreatic cancer progression through Snail1-mediated epithelial–mesenchymal transition and the Notch signaling pathway. Scientific Reports (2017).